Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $211.32 | 3 | 90.8% |
| Education | $21.31 | 1 | 9.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $121.51 | 1 | $0 (2018) |
| Foundation Medicine, Inc. | $65.91 | 1 | $0 (2019) |
| Clovis Oncology, Inc. | $23.90 | 1 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $21.31 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $21.31 | 1 | E.R. Squibb & Sons, L.L.C. ($21.31) |
| 2019 | $89.81 | 2 | Foundation Medicine, Inc. ($65.91) |
| 2018 | $121.51 | 1 | Genentech USA, Inc. ($121.51) |
All Payment Transactions
4 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2023 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Education | In-kind items and services | $21.31 | General |
| Category: Hematology | ||||||
| 11/05/2019 | Foundation Medicine, Inc. | FOUNDATIONACT (Device), FOUNDATIONFOCUS, FOUNDATIONONE CDX | Food and Beverage | Cash or cash equivalent | $65.91 | General |
| Category: ONCOLOGY | ||||||
| 04/01/2019 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: Oncology | ||||||
| 03/27/2018 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $121.51 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 113 | 194 | $60,022 | $15,982 |
| 2022 | 8 | 244 | 443 | $131,550 | $38,523 |
| 2021 | 5 | 256 | 424 | $129,368 | $39,421 |
| 2020 | 6 | 165 | 270 | $78,647 | $22,419 |
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 71 | 126 | $38,178 | $8,868 | 23.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 30 | 52 | $19,396 | $5,869 | 30.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 12 | 16 | $2,448 | $1,245 | 50.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 97 | 220 | $66,660 | $16,811 | 25.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 52 | 105 | $39,165 | $12,421 | 31.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 21 | 21 | $9,261 | $3,165 | 34.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 26 | 37 | $5,661 | $2,835 | 50.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 18 | $4,284 | $1,500 | 35.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 12 | 16 | $1,968 | $814.60 | 41.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 13 | $3,380 | $637.52 | 18.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 12 | 13 | $1,171 | $339.10 | 29.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 85 | 156 | $58,188 | $18,232 | 31.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 86 | 170 | $51,510 | $13,365 | 25.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 30 | 30 | $11,394 | $4,389 | 38.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 25 | 30 | $4,590 | $2,422 | 52.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 30 | 38 | $3,686 | $1,013 | 27.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 54 | 111 | $38,203 | $10,113 | 26.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 33 | 67 | $17,721 | $4,063 | 22.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 22 | 22 | $8,286 | $3,104 | 37.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 26 | 38 | $5,814 | $2,444 | 42.0% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 18 | 19 | $5,776 | $1,569 | 27.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 13 | $2,847 | $1,125 | 39.5% |
About Dr. Andre De Souza, M.D
Dr. Andre De Souza, M.D is a Hematology & Oncology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2012. The National Provider Identifier (NPI) number assigned to this provider is 1053676627.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andre De Souza, M.D has received a total of $232.63 in payments from pharmaceutical and medical device companies, with $21.31 received in 2023. These payments were reported across 4 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($211.32).
As a Medicare-enrolled provider, De Souza has provided services to 778 Medicare beneficiaries, totaling 1,331 services with total Medicare billing of $116,345. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Oklahoma City, OK
- Active Since 07/10/2012
- Last Updated 12/30/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1053676627
Products in Payments
- Avastin (Biological) $121.51
- FOUNDATIONACT (Device) $65.91
- Rubraca (Drug) $23.90
- REBLOZYL (Biological) $21.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Oklahoma City
Robert Reynolds, Md, MD
Hematology & Oncology — Payments: $14,579
Philip Comp, Md, MD
Hematology & Oncology — Payments: $13,151
Dr. Charles Hollen, M.d, M.D
Hematology & Oncology — Payments: $12,135
Jennifer Holter-Chakrabarty, Md, MD
Hematology & Oncology — Payments: $11,994
Dr. Saadia Chohan, Md, MD
Hematology & Oncology — Payments: $11,197
Abby Bova, Md, MD
Hematology & Oncology — Payments: $5,791